Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Positron Emission Tomography-Computed Tomography
100%
Prospective Study
100%
Fluorodeoxyglucose F 18
100%
Bladder Carcinoma
100%
Fluorodeoxyglucose
80%
Cystectomy
40%
Metastatic Carcinoma
30%
Overall Survival
20%
Retroperitoneal Lymph Node Dissection
20%
Recurrence Free Survival
20%
Disease Specific Survival
20%
Bladder
10%
Kaplan Meier Method
10%
Neoadjuvant Chemotherapy
10%
Preoperative Evaluation
10%
Survival Analysis
10%
Transitional Cell Carcinoma
10%
Log Rank Test
10%
Percutaneous Biopsy
10%
Morbidity
10%
Bone Scintigraphy
10%
Surgical Exploration
10%
Lymph Flow
10%
Polyethylene Terephthalate
10%
Chemotherapy
10%
Median Follow Up
10%
Keyphrases
Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
100%
Muscle-invasive Bladder Carcinoma
100%
18F-fluorodeoxyglucose Positron Emission Tomography/computed Tomography (18F-FDG PET/CT)
100%
Radical Cystectomy
37%
Overall Survival
25%
Lymphadenectomy
25%
Recurrence-free Survival
25%
Disease-specific Survival
25%
Upper Tract Urothelial Carcinoma
25%
Occult Metastatic Disease
25%
Chemotherapy
12%
Conventional CT
12%
Positive Predictive Value
12%
Negative Predictive Value
12%
Survival Analysis
12%
18F-fluorodeoxyglucose (18F-FDG)
12%
Kaplan-Meier Method
12%
Distant Metastasis
12%
Nave
12%
Open Surgical Repair
12%
Neoadjuvant Chemotherapy
12%
Treatment Decisions
12%
Log-rank Test
12%
Percutaneous Biopsy
12%
Bone Scintigraphy
12%
Cystectomy
12%
Surgical Exploration
12%
Lymphatic Spread
12%
Pathology Data
12%
Positron Emission Tomography/computed Tomography (PET/CT)
12%
Strongly Correlated
12%
Preoperative Assessment
12%
Novel Imaging
12%